RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $251

Benzinga Newsdesk www.benzinga.com Positive 92.6%

Neg 0% Neu 0% Pos 92.6%

RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $203 to $251.